092730 — NeoPharm Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousSmall CapSuper Stock

Annual income statement for NeoPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	83,240	81,625	87,931	85,033	97,105
Cost of Revenue
Gross Profit	60,104	58,642	62,386	58,380	65,385
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	60,528	59,723	65,511	63,601	71,811
Operating Profit	22,713	21,902	22,420	21,433	25,294
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	23,541	22,936	23,836	23,323	29,373
Provision for Income Taxes
Net Income After Taxes	19,245	18,131	17,713	17,027	23,213
Minority Interest
Net Income Before Extraordinary Items
Net Income	19,245	18,131	17,713	17,027	23,213
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	19,245	18,131	17,713	17,027	23,213
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2,572	2,298	2,266	2,176	2,967
Dividends per Share